Global Multiple Myeloma Market

Global Multiple Myeloma Market Size, Share, Growth Analysis, By Therapy(Targeted Therapy, Biologic Therapy), By Drug type(Immunomodulatory Drugs, Proteasome Inhibitors), By Distribution channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2024-2031


Report ID: SQMIG35I2293 | Region: Global | Published Date: April, 2024
Pages: 157 | Tables: 94 | Figures: 76

Global Multiple Myeloma Market Insights

Multiple Myeloma Market size was valued at USD 23.53 billion in 2019 and is poised to grow from USD 25.06 billion in 2023 to USD 44.17 billion by 2031, growing at a CAGR of 6.5% in the forecast period (2024-2031).

Multiple myeloma is a critical type of blood cancer that mostly targets plasma cells. It is an uncommon form of cancer. The number of diagnoses among patients is rising as a result of growing awareness of disease symptoms. As a result, several potentially blockbuster medications were introduced, and the treatment expertise of the leading Multiple Myeloma Market competitors increased. As per the Globocan 2020 information sheet, there were an expected 19,292,789 new cancer cases, with about 9,958,133 cancer-related deaths.

Furthermore, the International Agency for Research on Cancer (IARC) predicts that by 2031, the worldwide incidence of cancer will have increased to 27.5 million new cases and 16.3 million deaths. In the entire world, men are around 1.5 times more likely to have it than women. Although no single risk factor has been linked to multiple myeloma, suggested underlying causes include differences in health-risk behaviors like smoking and alcohol consumption as well as higher rates of obesity among males. The disease is more prevalent among the age group of older adults with median age i.e., between the age range 55 to 65 years.

Additionally, rising incidence rates of hematological cancer and rising demand for healthcare infrastructure, research, and treatment are the main drivers of the multiple myeloma market. Low treatment rates in developing countries are a limiting factor to the market expansion for the global multiple myeloma market.

US Multiple Myeloma Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Multiple Myeloma Market size was valued at USD 23.53 billion in 2019 and is poised to grow from USD 25.06 billion in 2023 to USD 44.17 billion by 2031, growing at a CAGR of 6.5% in the forecast period (2024-2031).

The global Multiple myeloma market is highly competitive. As a result, the global Multiple myeloma market has been witnessing the constant entry of new players over the years. In order to sustain the highly competitive environment, existing players differentiate themselves through innovation, quality, and technology. 'Sanofi', 'Novartis AG', 'Takeda Pharmaceutical Company Limited', 'Celgene Corporation (a subsidiary of Bristol-Myers Squibb)', 'Amgen Inc.', 'Johnson & Johnson', 'AbbVie Inc.', 'GlaxoSmithKline plc', 'Pfizer Inc.', 'Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson)', 'Bristol-Myers Squibb Company', 'Merck & Co., Inc.', 'Onyx Pharmaceuticals (a subsidiary of Amgen Inc.)', 'Millennium Pharmaceuticals (a subsidiary of Takeda Pharmaceutical Company Limited)', 'Spectrum Pharmaceuticals, Inc.', 'Karyopharm Therapeutics Inc.', 'Genmab A/S', 'Servier Pharmaceuticals LLC', 'AbbVie Biotechnology Ltd. (a subsidiary of AbbVie Inc.)', 'Janssen-Cilag International N.V. (a subsidiary of Johnson & Johnson)'

The use of monoclonal antibodies with a high safety profile to attack myeloma cells. The development of nanomedicine platforms, the increased use of microRNA therapies, and the ongoing development of efficient and safe medications are all contributing to the growth of the multiple myeloma market. When monoclonal antibodies and histone deacetylase (HDAC) inhibitors are added to the current treatment options, the medication market is expected to grow. Clinicians prefer biologic therapy with monoclonal antibodies such as Darzalex and Empliciti due to their well-documented clinical profile.

A rise in research and development activities is driving the expansion of the multiple myeloma market. This will present advantageous chances for the expansion of the multiple myeloma market. Along with this, an increase in drug releases and approvals will speed up the market's expansion. The introduction of monoclonal antibodies (mAbs), such as Empliciti and Darzalex, will present a significant growth opportunity for the market because they will not only give patients with multiple myeloma a new therapeutic option, but also increase the interval between relapses, extending the effectiveness of Revlimid and Velcade treatments. These patients will also have access to the second-generation proteasome inhibitors Ninlaro and Kyprolis, broadening their range of treatment options. The market and industry, which are currently under the control of Revlimid, an immunomodulator, and Velcade, a proteasome inhibitor.

Geographically, North America is projected to account for the highest proportion of the global Multiple Myeloma Market for multiple myeloma treatments due to significant growth in the incidence of the disease, high awareness of the need for early cancer detection and treatment, favorable reimbursement policies, and an advanced healthcare system. Due to its quicker approval times, favorable healthcare laws, and concentration of big businesses, Europe has been leading the market for multiple myeloma treatments. Multiple myeloma is more common in developed nations, which is fueling the expansion of the European market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Multiple Myeloma Market

Product ID: SQMIG35I2293

$5,300
BUY NOW GET FREE SAMPLE